SmocMabTM: Fully Human AntibodyTransgenic Mice Tailored to YourAntigen in 3 Months

Who We Are

GenoBioTX is a well-known contract research organization (CRO) providing genetically engineered animal models, and preclinical drug discovery services to biopharmaceutical companies and life science researchers.

Our Services

Generate KO HOM mice in just 3 months

  • Provision of at least 3 F0 homozygous mice per project within 3 months
  • Comprehensive and detailed report
  • Immediate phenotype analysis and self or high homology antigen immunization

Intergrated antibody discovery platform

  • Preparation of antigen and KO mouse
  • Animal immunization and hit generation
  • Lead Characterization
  • Cell line Development and antibody manufacture

YouMabTM fully human antibody transgenic mouse

  • Fully human antibodies produced efficiently
  • No need for humanization process
  • High affinity and specificity achieved
  • Streamlined and reliable discovery platform for high homology antigens

Antibody evaluation

  • Antibody characterization
  • Well-validated animal models
  • In vivo efficacy study
  • PK/PD test
  • Toxicity evaluation

Why choose us

  • Choose us for our unmatched expertise in animal model generation and antibody discovery, backed by years of experience in biomedical research.
  • Our state-of-the-art technology and proven track record ensure precise, reliable results, helping you accelerate your research and development.
  • With a focus on quality and efficiency, we provide customized solutions tailored to meet the unique demands of each project.

    News Center

    2025.04.02

    P53 Mutants, DNA Medicine, and Mobile Genetic Elements

    Register Link: https://www.eventbrite.com/e/genobiotx-april-2025-webinar-tickets-1310558388419?aff=oddtdtcreator Date: Wednesday, April 23rd, 2025; 2:00 pm EDT or 11:00 am PDT Meet Our Speaker: Dr. Li earned his Ph.D. in Molecular Biology in 1999 from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, followed by postdoctoral training at Yale University (1999–2004). With over 20 years of experience in cancer molecular […]

    2024.11.01

    Why IL-2 Still Holds Promise in Therapeutics of Cancer and Autoimmunity

    Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]

    Email Back to top